AliveCor recently announced results from several independent studies that showed how one of their flagship products, Kardia Mobile, can positively impact those who may have atrial fibrillation (AF). Early diagnosis of AF is imperative and can help prevent more serious conditions like heart failure, strokes, and hospitalization.
Kardia works by wirelessly connecting a pulse-monitoring pad to a smartphone, tablet, and wearables allowing patients to perform a self-administered EKG test almost anywhere. The results are displayed live on the screen and are, according to the studies, very accurate.
The findings were announced at this year’s ESC Congress in Barcelona.
One study from the Cleveland Clinic showed that Kardia Mobile’s accuracy was similar to that of a physician. They also found that Kardia “lessened AFib-diagnosis anxiety.”
In a large study of over 12,000 participants, the Chinese University of Hong Kong’s team found that Kardia’s 30-second EKG was able to diagnose patients with AF who previously had not been diagnosed. Another research team in Hong Kong from Princess Margaret Hospital also found that participants were found to have AF even though they were previously undiagnosed. Using a group of over 10,000 non-medical professionals, they also found that Kardia was easy to use.
We’ve previously talked about consumer wearables that let patients to do EKGs from the comfort of their own homes, but AliveCor now states that it is the most “clinically-validated EKG solution on the market.” While that claim may be hyperbolic, the results from these studies are excellent news for the mobile healthcare company.